Search research articles
Contact Us
Filters
Showing results (71-80 of 133) with videos related to
Page
of 14
Sort By:
Nature Medicine
|
November 10, 2009
Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype
Daniel T Starczynowski, Florian Kuchenbauer, Bob Argiropoulos, et al.
Leukemia Research
|
May 14, 2014
Lenalidomide and metronomic melphalan for CMML and higher risk MDS: a phase 2 clinical study with biomarkers of angiogenesis
Rena Buckstein, Robert Kerbel, Matthew Cheung, et al.
British Journal of Haematology
|
January 31, 2018
Autologous stem cell transplant and combination immunotherapy of rituximab and interferon-α induces prolonged clinical and molecular remissions in patients with follicular lymphoma
Liam Smyth, Rena Buckstein, Nancy Pennell, et al.
Leukemia & Lymphoma
|
January 30, 2010
A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study
Michael Crump, David Hedley, Suzanne Kamel-Reid, et al.
Annals of Hematology
|
November 19, 2024
Supportive care strategies in myelodysplastic syndromes and acute myeloid leukemia in older adults: a national survey of Canadian hematologists
Anna R Blankstein, Nora Choi, Lee Mozessohn, et al.
Leukemia & Lymphoma
|
June 9, 2016
Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12<sup/>
Tara Baetz, Bingshu E Chen, Stephen Couban, et al.
Journal of Hematology & Oncology
|
October 24, 2012
Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial
Pier Luigi Zinzani, Nuriet K Khuageva, Huaqing Wang, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 30, 2015
Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study
Rena Buckstein, Graeme Fraser, Matthew Cheung, et al.
Leukemia & Lymphoma
|
March 12, 2014
Sunitinib malate in patients with intermediate-2 or high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia
Karen W L Yee, John M Storring, Rena Buckstein, et al.
Leukemia
|
September 26, 2023
Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts
Uwe Platzbecker, Valeria Santini, Rami S Komrokji, et al.
Page
of 14
Search research articles
Search
Showing results (71-80 of 133) with videos related to
Sort By:
Page
of 14
Nature Medicine
|
November 10, 2009
Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype
Daniel T Starczynowski, Florian Kuchenbauer, Bob Argiropoulos, et al.
Leukemia Research
|
May 14, 2014
Lenalidomide and metronomic melphalan for CMML and higher risk MDS: a phase 2 clinical study with biomarkers of angiogenesis
Rena Buckstein, Robert Kerbel, Matthew Cheung, et al.
British Journal of Haematology
|
January 31, 2018
Autologous stem cell transplant and combination immunotherapy of rituximab and interferon-α induces prolonged clinical and molecular remissions in patients with follicular lymphoma
Liam Smyth, Rena Buckstein, Nancy Pennell, et al.
Leukemia & Lymphoma
|
January 30, 2010
A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study
Michael Crump, David Hedley, Suzanne Kamel-Reid, et al.
Annals of Hematology
|
November 19, 2024
Supportive care strategies in myelodysplastic syndromes and acute myeloid leukemia in older adults: a national survey of Canadian hematologists
Anna R Blankstein, Nora Choi, Lee Mozessohn, et al.
Leukemia & Lymphoma
|
June 9, 2016
Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12<sup/>
Tara Baetz, Bingshu E Chen, Stephen Couban, et al.
Journal of Hematology & Oncology
|
October 24, 2012
Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial
Pier Luigi Zinzani, Nuriet K Khuageva, Huaqing Wang, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 30, 2015
Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study
Rena Buckstein, Graeme Fraser, Matthew Cheung, et al.
Leukemia & Lymphoma
|
March 12, 2014
Sunitinib malate in patients with intermediate-2 or high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia
Karen W L Yee, John M Storring, Rena Buckstein, et al.
Leukemia
|
September 26, 2023
Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts
Uwe Platzbecker, Valeria Santini, Rami S Komrokji, et al.
Page
of 14